187 related articles for article (PubMed ID: 34912073)
1. Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours.
Fankhauser CD; Christiansen AJ; Rothermundt C; Cathomas R; Wettstein MS; Grossmann NC; Grogg JB; Templeton AJ; Hirschi-Blickenstorfer A; Lorch A; Gillessen S; Moch H; Beyer J; Hermanns T
Br J Cancer; 2022 May; 126(8):1140-1144. PubMed ID: 34912073
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker.
Spiekermann M; Belge G; Winter N; Ikogho R; Balks T; Bullerdiek J; Dieckmann KP
Andrology; 2015 Jan; 3(1):78-84. PubMed ID: 25187505
[TBL] [Abstract][Full Text] [Related]
3. Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?
Radtke A; Cremers JF; Kliesch S; Riek S; Junker K; Mohamed SA; Anheuser P; Belge G; Dieckmann KP
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2383-2392. PubMed ID: 28819887
[TBL] [Abstract][Full Text] [Related]
4. Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management.
Badia RR; Abe D; Wong D; Singla N; Savelyeva A; Chertack N; Woldu SL; Lotan Y; Mauck R; Ouyang D; Meng X; Lewis CM; Majmudar K; Jia L; Kapur P; Xu L; Frazier AL; Margulis V; Strand DW; Coleman N; Murray MJ; Amatruda JF; Lafin JT; Bagrodia A
J Urol; 2021 Jan; 205(1):137-144. PubMed ID: 32856980
[TBL] [Abstract][Full Text] [Related]
5. Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer.
Lobo J; Leão R; Gillis AJM; van den Berg A; Anson-Cartwright L; Atenafu EG; Kuhathaas K; Chung P; Hansen A; Bedard PL; Jewett MAS; Warde P; O'Malley M; Sweet J; Looijenga LHJ; Hamilton RJ
Eur Urol Oncol; 2021 Jun; 4(3):483-491. PubMed ID: 33288479
[TBL] [Abstract][Full Text] [Related]
6. microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients.
van Agthoven T; Eijkenboom WMH; Looijenga LHJ
Cell Oncol (Dordr); 2017 Aug; 40(4):379-388. PubMed ID: 28612337
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of miR-371a-3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection.
Konneh B; Lafin JT; Howard J; Gerald T; Amini A; Savelyeva A; Woldu SL; Lewis CM; Jia L; Margulis V; Coleman N; Scarpini C; Frazier AL; Murray MJ; Amatruda JF; Bagrodia A
Andrology; 2023 May; 11(4):634-640. PubMed ID: 36254623
[TBL] [Abstract][Full Text] [Related]
8. The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1.
Radtke A; Hennig F; Ikogho R; Hammel J; Anheuser P; Wülfing C; Belge G; Dieckmann KP
Urol Int; 2018; 100(4):470-475. PubMed ID: 29698973
[TBL] [Abstract][Full Text] [Related]
9. Germ cell tumour subtypes display differential expression of microRNA371a-3p.
Vilela-Salgueiro B; Barros-Silva D; Lobo J; Costa AL; Guimarães R; Cantante M; Lopes P; Braga I; Oliveira J; Henrique R; Jerónimo C
Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685967
[TBL] [Abstract][Full Text] [Related]
10. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.
Dieckmann KP; Radtke A; Geczi L; Matthies C; Anheuser P; Eckardt U; Sommer J; Zengerling F; Trenti E; Pichler R; Belz H; Zastrow S; Winter A; Melchior S; Hammel J; Kranz J; Bolten M; Krege S; Haben B; Loidl W; Ruf CG; Heinzelbecker J; Heidenreich A; Cremers JF; Oing C; Hermanns T; Fankhauser CD; Gillessen S; Reichegger H; Cathomas R; Pichler M; Hentrich M; Eredics K; Lorch A; Wülfing C; Peine S; Wosniok W; Bokemeyer C; Belge G
J Clin Oncol; 2019 Jun; 37(16):1412-1423. PubMed ID: 30875280
[TBL] [Abstract][Full Text] [Related]
11. MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients.
Terbuch A; Adiprasito JB; Stiegelbauer V; Seles M; Klec C; Pichler GP; Resel M; Posch F; Lembeck AL; Stöger H; Szkandera J; Pummer K; Bauernhofer T; Hutterer GC; Gerger A; Stotz M; Pichler M
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321995
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of plasma miR-371a-3p in germ cell tumors.
Mego M; van Agthoven T; Gronesova P; Chovanec M; Miskovska V; Mardiak J; Looijenga LHJ
J Cell Mol Med; 2019 Feb; 23(2):1128-1136. PubMed ID: 30536846
[TBL] [Abstract][Full Text] [Related]
13. Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours.
Dieckmann KP; Radtke A; Spiekermann M; Balks T; Matthies C; Becker P; Ruf C; Oing C; Oechsle K; Bokemeyer C; Hammel J; Melchior S; Wosniok W; Belge G
Eur Urol; 2017 Feb; 71(2):213-220. PubMed ID: 27495845
[TBL] [Abstract][Full Text] [Related]
14. Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study.
Belge G; Dumlupinar C; Nestler T; Klemke M; Törzsök P; Trenti E; Pichler R; Loidl W; Che Y; Hiester A; Matthies C; Pichler M; Paffenholz P; Kluth L; Wenzel M; Sommer J; Heinzelbecker J; Schriefer P; Winter A; Zengerling F; Kramer MW; Lengert M; Frey J; Heidenreich A; Wülfing C; Radtke A; Dieckmann KP
Clin Cancer Res; 2024 Jan; 30(2):404-412. PubMed ID: 37967143
[TBL] [Abstract][Full Text] [Related]
15. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer.
Syring I; Bartels J; Holdenrieder S; Kristiansen G; Müller SC; Ellinger J
J Urol; 2015 Jan; 193(1):331-7. PubMed ID: 25046619
[TBL] [Abstract][Full Text] [Related]
16. High Expression of microRNA-371a-3p in Cystic Fluid of Post-Chemotherapy Teratoma with Concurrent Normal Serum Levels in Patients with Non-Seminomatous Testicular Germ Cell Tumours.
Dieckmann KP; Hennig F; Anheuser P; Gehrckens R; Viehweger F; Wülfing C; Belge G
Urol Int; 2021; 105(1-2):21-26. PubMed ID: 33049748
[TBL] [Abstract][Full Text] [Related]
17. The metastatic potential of seminomatous germ cell tumours is associated with a specific microRNA pattern.
Ernst S; Heinzelmann J; Bohle RM; Weber G; Stöckle M; Junker K; Heinzelbecker J
Andrology; 2020 Nov; 8(6):1687-1698. PubMed ID: 32530514
[TBL] [Abstract][Full Text] [Related]
18. Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence.
Christiansen AJ; Lobo J; Fankhauser CD; Rothermundt C; Cathomas R; Batavia AA; Grogg JB; Templeton AJ; Hirschi-Blickenstorfer A; Lorch A; Gillessen S; Moch H; Beyer J; Hermanns T
Front Oncol; 2022; 12():1056823. PubMed ID: 36568207
[TBL] [Abstract][Full Text] [Related]
19. Analytical Validation and Performance Characteristics of Molecular Serum Biomarkers, miR-371a-3p and miR-372-3p, for Male Germ Cell Tumors, in a Clinical Laboratory Setting.
Ye F; Feldman DR; Valentino A; So R; Bromberg M; Khan S; Funt SA; Sheinfeld J; Solit DB; Pessin MS; Peerschke EI
J Mol Diagn; 2022 Aug; 24(8):867-877. PubMed ID: 35934321
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA miR-371a-3p - A Novel Serum Biomarker of Testicular Germ Cell Tumors: Evidence for Specificity from Measurements in Testicular Vein Blood and in Neoplastic Hydrocele Fluid.
Dieckmann KP; Spiekermann M; Balks T; Ikogho R; Anheuser P; Wosniok W; Loening T; Bullerdiek J; Belge G
Urol Int; 2016; 97(1):76-83. PubMed ID: 26989896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
